Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas

Inclusion Criteria: * Histological diagnosis of primary tumor as high-grade gliomas (WHO III or IV) * All patients should complete radiation therapy for primary gliomas. * MRI showed unequivocal evidence of tumor recurrence or progression. * The time to be enrolled should be more than 90 days after the radiation therapy. * Written informed consent * Eastern Cooperative Oncology Group(ECOG) score: 0-2 * The patients with recurrent gliomas were treated without dose-dense TMZ therapy before enrollment. * Surgical interventions for recurrent gliomas are permitted and patients with no residual tumor are permitted Exclusion Criteria: * Abnormal function of liver or renal (value more than 1.5 fold normal upper limit) * Blood routing: Hb \< 90g/L, absolute neutrophil count≤1.5\*10\^9/L, platelet \< 100\*10\^9/L * Pregnant or lactating women * Allergic to administered drugs * Radiation therapy in the previous 90 days before enrollment * The patients with recurrent gliomas were treated with dose-dense TMZ therapy before enrollment. * Acute infection in need of antibiotics intravenously * Participation in other clinical trials in the 90 days before enrollment